A Phase 2 interventional study of BMS-986036 and Placebo in Non-Alcoholic Steatohepatitis, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-26.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Non-alcoholic Fatty Liver Disease by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Bristol-Myers Squibb.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Bristol-Myers Squibb, this one is the 11th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 2, and was the 3rd registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 11 studies in Non-alcoholic Fatty Liver Disease by Bristol-Myers Squibb is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 21 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7
First in 2015; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 40 across the 11 interventional studies. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered as specified on specified days
Drug: BMS-986036
Administered as specified on specified days
Drug: Placebo
BMS-986036 20 mg QD
Placebo QD
Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16
The mean change in percent hepatic fat fraction (%) by MRI from baseline to Week 16 was assessed for each arm. A longitudinal repeated measures analysis was used to analyze the change in hepatic fat fraction (%) at Week 16 from baseline in the treated population who have both a baseline and at least one post-baseline measurement.
Time frame: From Day 1 to Day 112
Number of Participants With Adverse Events (AEs)
The number of participants with on-study AEs was reported for each arm.
Time frame: From first dose to date of last dose plus 30 days
Number of Participants With Serious Adverse Events (SAEs)
The number of participants with on-study SAEs was reported for each arm.
Time frame: From first dose to date of last dose plus 30 days
Number of Participants With Injection Site Reactions
The number of participants with on-study injection site reactions was reported for each arm.
Time frame: From first dose to date of last dose plus 30 days
Number of Participants With Adverse Events Leading to Discontinuation
The number of participants with on-study AEs leading to discontinuation was reported for each arm.
Time frame: From first dose to date of last dose plus 30 days
Number of Deaths
The number of deaths was reported for each arm.
Time frame: From first dose to date of last dose plus 30 days
Number of Participants With Marked Laboratory Abnormalities
The number of participants whose worst toxicity grade increased from baseline to grade 3 or 4 (Toxicity Scale: DAIDS Version 1.0) is reported for each arm.
Time frame: From first dose to date of last dose plus 30 days
Number of Participants With Vital Sign Abnormalities
The number of participants with out-of-range vital signs noted during interim or final vital sign assessments was reported for each arm.
Time frame: From first dose to date of last dose plus 30 days
Number of Participants With Electrocardiogram (ECG) Abnormalities
The number of participants with out-of-range ECG intervals observed during interim or final electrocardiogram assessments was reported for each arm.
Time frame: From first dose to date of last dose plus 30 days
Number of Participants With Physical Examination Abnormalities
The number of participants with abnormalities observed during interim or final physical examination assessments is reported for each arm.
Time frame: From first dose to date of last dose plus 30 days
Mean Percent Change From Baseline in Bone Mineral Density by Dual Energy X-Ray Absorptiometry (DXA)
The mean percent change in bone mineral density from baseline to day 112 reported for each arm.
Time frame: From Day 1 to Day 112
Geometric Mean of Trough Observed Plasma Concentration (Ctrough) of BMS-986036 at Day 112
The observed serum concentration of BMS-986036 before the next dose is administered (pre-dose concentration) was assessed for both C-terminal intact and total molecule. Geometric means are presented for each arm.
Time frame: From Day 1 to Day 112
Number of Participants With Positive Anti-BMS-986036 Antibody (ADA) Response at Day 142
Participants were monitored for antibodies to study medication using a validated ADA homogenous bridge assay with BMS-986036 and electrochemical luminescence detection. The number of treated participants with positive Anti-BMS-986036 antibody titers up to Day 142 with regards to baseline was reported for each arm.
Time frame: From Day 1 to Day 142
Number of Participants With Positive Anti-FGF21 Antibody Response at Day 142
Participants were monitored for antibodies to FGF21 using a validated homogenous bridge assay with Met-FGF21 (recombinant produced) and electrochemical luminescence detection. The number of treated participants with positive Anti-FGF21 antibody titers up to Day 142 with regards to baseline was reported for each arm.
Time frame: From Day 1 to Day 142
| Milestone | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Started | 1 | 2 |
| Completed | 1 | 2 |
| Not completed | 0 | 0 |
| Milestone | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Started | 1 | 2 |
| Completed | 1 | 2 |
| Not completed | 0 | 0 |
The mean change in percent hepatic fat fraction (%) by MRI from baseline to Week 16 was assessed for each arm. A longitudinal repeated measures analysis was used to analyze the change in hepatic fat fraction (%) at Week 16 from baseline in the treated population who have both a baseline and at least one post-baseline measurement.
| percentage | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Mean Change in Percent Hepatic Fat Fraction (%) by Magnetic Resonance Imaging (MRI) From Baseline to Week 16 | NA (NA to NA) | NA (NA to NA) |
The number of participants with on-study AEs was reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | NA | NA |
The number of participants with on-study SAEs was reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | NA | NA |
The number of participants with on-study injection site reactions was reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Injection Site Bruising | NA | NA |
| Injection Site Erythema | NA | NA |
| Injection Site Reaction | NA | NA |
| Injection Site Pain | NA | NA |
| Injection Site Rash | NA | NA |
| Injection Site Swelling | NA | NA |
The number of participants with on-study AEs leading to discontinuation was reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Number of Participants With Adverse Events Leading to Discontinuation | NA | NA |
The number of deaths was reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Number of Deaths | NA | NA |
The number of participants whose worst toxicity grade increased from baseline to grade 3 or 4 (Toxicity Scale: DAIDS Version 1.0) is reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Alanine Aminotransferase (ALT) | NA | NA |
| Glucose, Fasting - high | NA | NA |
The number of participants with out-of-range vital signs noted during interim or final vital sign assessments was reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Number of Participants With Vital Sign Abnormalities | NA | NA |
The number of participants with out-of-range ECG intervals observed during interim or final electrocardiogram assessments was reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| PR > 200 msec | NA | NA |
| QRS > 120 msec | NA | NA |
| QT > 500 msec | NA | NA |
| QTcF > 450 msec | NA | NA |
| QT change from baseline > 30 msec | NA | NA |
| QTcF change from baseline > 30 msec | NA | NA |
The number of participants with abnormalities observed during interim or final physical examination assessments is reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Number of Participants With Physical Examination Abnormalities | NA | NA |
The mean percent change in bone mineral density from baseline to day 112 reported for each arm.
| Percentage | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Mean Percent Change From Baseline in Bone Mineral Density by Dual Energy X-Ray Absorptiometry (DXA) | NA ± NA | NA ± NA |
The observed serum concentration of BMS-986036 before the next dose is administered (pre-dose concentration) was assessed for both C-terminal intact and total molecule. Geometric means are presented for each arm.
| ng/mL | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| C-Terminal Intact | NA ± NA | NA ± NA |
| Total | NA ± NA | NA ± NA |
Participants were monitored for antibodies to study medication using a validated ADA homogenous bridge assay with BMS-986036 and electrochemical luminescence detection. The number of treated participants with positive Anti-BMS-986036 antibody titers up to Day 142 with regards to baseline was reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Number of Participants With Positive Anti-BMS-986036 Antibody (ADA) Response at Day 142 | NA | NA |
Participants were monitored for antibodies to FGF21 using a validated homogenous bridge assay with Met-FGF21 (recombinant produced) and electrochemical luminescence detection. The number of treated participants with positive Anti-FGF21 antibody titers up to Day 142 with regards to baseline was reported for each arm.
| Participants | BMS-986036 20 mg QD | Placebo 20 mg QD |
|---|---|---|
| Number of Participants With Positive Anti-FGF21 Antibody Response at Day 142 | NA | NA |
Collected over Non-serious adverse events after first dose of study medication and within 7 days of last dose and serious adverse events after first dose of study medication and within 30 days of last dose (approximately 4 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BMS-986036 20 mg QD | — | — | — |
| Placebo 20 mg QD | — | — | — |
| Age, Continuous(Years) | BMS-986036 20 mg QD | Placebo 20 mg QD | Total |
|---|---|---|---|
| Mean | 35 ± NA | 49.5 ± 2.12 | 44.67 ± 8.50 |
| Age, Customized(Participants) | BMS-986036 20 mg QD | Placebo 20 mg QD | Total |
|---|---|---|---|
| < 65 years of age | 1 | 2 | 3 |
| >= 65 years of age | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | BMS-986036 20 mg QD | Placebo 20 mg QD | Total |
|---|---|---|---|
| Female | 1 | 2 | 3 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | BMS-986036 20 mg QD | Placebo 20 mg QD | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BMS-986036 20 mg QD | Placebo 20 mg QD | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 2 | 3 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2015 to primary completion in Jan 2017, 20 months.
Results were first posted in Feb 2020, 3 years 1 month after primary completion. A results delay was requested in Jan 2018.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 20 months is close to that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegbelfermin
Non-alcoholic Fatty Liver Disease →